CAM
TCRT icon

Concorde Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Concorde Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-237
Closed -$61K – 159
2022
Q3 		$61K Buy
+237
New +$68.8K 0.07% 137

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Concorde Asset Management's TCRT Position: Q4 2022 in Review

Concorde Asset Management sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 237 shares — an estimated $61K sold.

Concorde Asset Management first reported a position in TCRT in Q3 2022 and held it in 1 quarter. The position peaked at $61K in Q3 2022. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Concorde Asset Management reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Concorde Asset Management sold 237 Alaunos Therapeutics shares in Q4 2022, an estimated $61K.
  • Concorde Asset Management first reported a position in Alaunos Therapeutics in Q3 2022 and held it in 1 quarter.
  • Concorde Asset Management's Alaunos Therapeutics position peaked at $61K in Q3 2022.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Concorde Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.